{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:01:14Z","timestamp":1792522874602,"version":"4.5.0"},"reference-count":44,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title><jats:p>All measles-containing vaccines are associated with several types of adverse events, including seizure, fever, and immune thrombocytopenia purpura (ITP). Because the measles-mumps-rubella-varicella (MMRV) vaccine compared with the separate measles-mumps-rubella (MMR) and varicella (MMR + V) vaccine increases a toddler\u2019s risk for febrile seizures, we investigated whether MMRV is riskier than MMR + V and whether either vaccine elevates the risk for additional safety outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Study children were aged 12 to 23 months in the Vaccine Safety Datalink from 2000 to 2012. Nine study outcomes were investigated: 7 main outcomes (anaphylaxis, ITP, ataxia, arthritis, meningitis\/encephalitis, acute disseminated encephalomyelitis, and Kawasaki disease), seizure, and fever. Comparing MMRV with MMR + V, relative risk was estimated by using stratified exact binomial tests. Secondary analyses examined post-MMRV or MMR + V risk versus comparison intervals; risk and comparison intervals were then contrasted for MMRV versus MMR+V.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>We evaluated 123\u2009200 MMRV and 584\u2009987 MMR + V doses. Comparing MMRV with MMR + V, risks for the 7 main outcomes were not significantly different. Several outcomes had few or zero postvaccination events. Comparing risk versus comparison intervals, ITP risk was higher after MMRV (odds ratio [OR]: 11.3 [95% confidence interval (CI): 1.9 to 68.2]) and MMR + V (OR: 10 [95% CI: 4.5 to 22.5]) and ataxia risk was lower after both vaccines (MMRV OR: 0.8 [95% CI: 0.5 to 1]; MMR + V OR: 0.8 [95% CI: 0.7 to 0.9]). Compared with MMR + V, MMRV increased risk of seizure and fever 7 to 10 days after vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>This study did not identify any new safety concerns comparing MMRV with MMR + V or after either the MMRV or the MMR + V vaccine. This study provides reassurance that these outcomes are unlikely after either vaccine.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2014-1822","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T01:10:15Z","timestamp":1420506615000},"page":"e321-e329","source":"Crossref","is-referenced-by-count":47,"title":["Safety of Measles-Containing Vaccines in 1-Year-Old Children"],"prefix":"10.1542","volume":"135","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Lewis","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Fireman","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Hambidge","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Colorado Institute for Health Research, Denver and Department of Ambulatory Care Services, Denver Health, Denver, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Naleway","sequence":"additional","affiliation":[{"name":"The Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Group Health Cooperative and the University of Washington, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Belongia","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Foundation, Marshfield, Wisconsin;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Katherine","family":"Yih","sequence":"additional","affiliation":[{"name":"Harvard Pilgrim Health Care Institute, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Nordin","sequence":"additional","affiliation":[{"name":"HealthPartners Research Foundation, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulin C.","family":"Hechter","sequence":"additional","affiliation":[{"name":"Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Weintraub","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Baxter","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"issue":"9","key":"2021120907022091000_B1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMoa003077","article-title":"The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.","volume":"345","author":"Barlow","year":"2001","journal-title":"N Engl J Med"},{"issue":"8949","key":"2021120907022091000_B2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(95)90471-9","article-title":"A new method for active surveillance of adverse events from diphtheria\/tetanus\/pertussis and measles\/mumps\/rubella vaccines.","volume":"345","author":"Farrington","year":"1995","journal-title":"Lancet"},{"issue":"5","key":"2021120907022091000_B3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1542\/peds.88.5.881","article-title":"Risk of seizures after measles-mumps-rubella immunization.","volume":"88","author":"Griffin","year":"1991","journal-title":"Pediatrics"},{"issue":"3","key":"2021120907022091000_B4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.292.3.351","article-title":"MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis.","volume":"292","author":"Vestergaard","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"2021120907022091000_B5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.inf.0000220209.35074.0b","article-title":"The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.","volume":"25","author":"Lieberman","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"2021120907022091000_B6","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.inf.0000172902.25009.a1","article-title":"Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children.","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021120907022091000_B7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.inf.0000207857.10947.1f","article-title":"Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate\/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.","volume":"25","author":"Shinefield","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2021120907022091000_B8","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"2021120907022091000_B9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11530350-000000000-00000","article-title":"Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy.","volume":"33","author":"Bertuola","year":"2010","journal-title":"Drug Saf"},{"issue":"2","key":"2021120907022091000_B10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1542\/peds.2011-1111","article-title":"The risk of immune thrombocytopenic purpura after vaccination in children and adolescents.","volume":"129","author":"O\u2019Leary","year":"2012","journal-title":"Pediatrics"},{"issue":"4","key":"2021120907022091000_B11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents.","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"issue":"7317","key":"2021120907022091000_B12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.323.7317.869a","article-title":"MMR immunisation. True anaphylaxis to MMR vaccine is extremely rare.","volume":"323","author":"Carapetis","year":"2001","journal-title":"BMJ"},{"issue":"6","key":"2021120907022091000_B13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.110.6.e71","article-title":"Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.","volume":"110","author":"Pool","year":"2002","journal-title":"Pediatrics"},{"key":"2021120907022091000_B14","volume-title":"Adverse Effects of Vaccines: Evidence and Causality","author":"Institute of Medicine","year":"2011"},{"issue":"RR-15","key":"2021120907022091000_B15","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"55","author":"Kroger","year":"2006","journal-title":"MMWR Recommendations and Reports"},{"issue":"1","key":"2021120907022091000_B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/INF.0b013e3181af8605","article-title":"Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine.","volume":"29","author":"Belongia","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"2021120907022091000_B17","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events.","volume":"45","author":"Lieu","year":"2007","journal-title":"Med Care"},{"issue":"10","key":"2021120907022091000_B18","first-page":"258","article-title":"Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"2021120907022091000_B19","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"2021120907022091000_B20","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"key":"2021120907022091000_B21","first-page":"1","article-title":"Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Marin","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"2021120907022091000_B22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1542\/peds.2011-3198","article-title":"Measles-containing vaccines and febrile seizures in children age 4 to 6 years.","volume":"129","author":"Klein","year":"2012","journal-title":"Pediatrics"},{"issue":"1","key":"2021120907022091000_B23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.vaccine.2012.07.024","article-title":"Biologically plausible and evidence-based risk intervals in immunization safety research.","volume":"31","author":"Rowhani-Rahbar","year":"2012","journal-title":"Vaccine"},{"issue":"22","key":"2021120907022091000_B24","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.vaccine.2013.03.040","article-title":"Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.","volume":"31","author":"Tseng","year":"2013","journal-title":"Vaccine"},{"issue":"46","key":"2021120907022091000_B25","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"2021120907022091000_B26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archpediatrics.2012.1451","article-title":"Safety of quadrivalent human papillomavirus vaccine administered routinely to females.","volume":"166","author":"Klein","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"20","key":"2021120907022091000_B27","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2012.02.080","article-title":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age.","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"issue":"19","key":"2021120907022091000_B28","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.vaccine.2012.02.039","article-title":"A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"2021120907022091000_B29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/aje\/kwp173","article-title":"Influenza vaccination and mortality: differentiating vaccine effects from bias.","volume":"170","author":"Fireman","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2021120907022091000_B30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/aje\/kws011","article-title":"Immunization and Bell\u2019s palsy in children: a case-centered analysis.","volume":"175","author":"Rowhani-Rahbar","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2021120907022091000_B31"},{"issue":"158","key":"2021120907022091000_B32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference.","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"issue":"8","key":"2021120907022091000_B33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"6","key":"2021120907022091000_B34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.vaccine.2013.12.011","article-title":"Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.","volume":"32","author":"Schink","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"2021120907022091000_B35","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-3429","article-title":"Timely versus delayed early childhood vaccination and seizures.","volume":"133","author":"Hambidge","year":"2014","journal-title":"Pediatrics"},{"key":"2021120907022091000_B36"},{"issue":"1","key":"2021120907022091000_B37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1651-2227.2000.tb01188.x","article-title":"Gait disturbance interpreted as cerebellar ataxia after MMR vaccination at 15 months of age: a follow-up study.","volume":"89","author":"Plesner","year":"2000","journal-title":"Acta Paediatr"},{"issue":"3","key":"2021120907022091000_B38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/adc.2003.048165","article-title":"No evidence of an association between MMR vaccine and gait disturbance.","volume":"90","author":"Miller","year":"2005","journal-title":"Arch Dis Child"},{"issue":"13","key":"2021120907022091000_B39","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.vaccine.2009.01.019","article-title":"Acute cerebellar ataxia in the Netherlands: a study on the association with vaccinations and varicella zoster infection.","volume":"27","author":"van der Maas","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"2021120907022091000_B40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pediatrneurol.2009.07.012","article-title":"Neurologic varicella complications before routine immunization in Germany.","volume":"42","author":"Rack","year":"2010","journal-title":"Pediatr Neurol"},{"issue":"5","key":"2021120907022091000_B41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.2.5.3246","article-title":"Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).","volume":"2","author":"Kuter","year":"2006","journal-title":"Hum Vaccin"},{"issue":"26","key":"2021120907022091000_B42","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.vaccine.2012.03.080","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.","volume":"30","author":"Klein","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"2021120907022091000_B43","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1097\/INF.0b013e318259fc8a","article-title":"Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.","volume":"31","author":"Blatter","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2021120907022091000_B44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamapediatrics.2013.2745","article-title":"Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children.","volume":"167","author":"Rowhani-Rahbar","year":"2013","journal-title":"JAMA Pediatr"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/e321\/1058397\/peds_2014-1822.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/e321\/1058397\/peds_2014-1822.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:39:21Z","timestamp":1650933561000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/135\/2\/e321\/33468\/Safety-of-Measles-Containing-Vaccines-in-1-Year"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-1822","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,1]]}}}